



GAU 1624\$

Practitioner's ~~Booklet~~ No. 49592 (71878)

PATENT

45

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: D. Williams et al.
SERIAL NO.: 09/506,362 GROUP: 1624
FILED: February 15, 2000 EXAMINER: J. Ford
FOR: APOPTOSIS-INDUCING COMPOUNDS

Honorable Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL

1. Transmitted herewith is an Amendment for this application.

STATUS

2. Applicant is
[] a small entity. A statement:
[] is attached.
[] was already filed.
[X] other than a small entity.

RECEIVED
JAN 15 2002
TECH CENTER 1600/2800

EXTENSION OF TERM

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) — If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

FACSIMILE

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: October 18, 2001

Christine C. O'Day

(type or print name of person certifying)



#16 A

Docket No. 49592 (71878)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: D. Williams, et al.

SERIAL NO.: 09/506,362

ART UNIT: 1624

FILED: February 15, 2000

EXAMINER: J. Ford

FOR: APOPTOSIS-INDUCING COMPOUNDS

Honorable Commissioner of Patents and Trademarks
Washington, DC 20231

Sir:

RECEIVED
JAN 15 2002
TECH CENTER 1600/2900

AMENDMENT

In response to the Office Action issued on April 18, 2001, Applicants kindly request that the application be amended as follows:

IN THE CLAIMS:

Kindly amend the noted claims as follows:

Kindly cancel claims 1-19, without prejudice or disclaimer.

Kindly add new claims 20-32.

20. A pharmaceutical composition for inducing apoptosis comprising a therapeutically effective amount of a compound having the general formula (I):

